Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI

Area of Science:

• Infectious Diseases
• Microbiology
• Gastroenterology

Background:

• Clostridium difficile infection (CDI) recurrence rates range from 12% to 40%, posing a significant clinical challenge.
• Traditional CDI treatments include vancomycin or alternative antibiotics, with fecal microbiota transplantation emerging as a safe alternative.
• New strategies for preventing recurrent CDI (rCDI) include novel antimicrobials like fidaxomicin and monoclonal antibodies such as bezlotoxumab.

Purpose of the Study:

• To review the current epidemiology, clinical impact, and risk factors of rCDI.
• To discuss current and emerging treatment and prevention strategies for rCDI.
• To identify barriers hindering the optimal use of available rCDI resources.

Main Methods:

• Literature review of current epidemiology and clinical impact of rCDI.
• Analysis of established and emerging therapeutic options for CDI and rCDI.
• Discussion of challenges in patient selection for advanced therapies.

Main Results:

• rCDI recurrence rates are substantial, necessitating improved management strategies.
• Fidaxomicin and bezlotoxumab represent promising advancements in rCDI prevention.
• Uncertainty in patient selection remains a significant hurdle for implementing new therapies.

Conclusions:

• Effective management of rCDI requires a comprehensive understanding of its epidemiology and risk factors.
• Emerging therapies offer new hope for preventing CDI recurrence, but optimal patient selection is critical.
• Addressing barriers to resource utilization is essential for improving outcomes in patients with rCDI.